

A pleiotropic variant in *DNAJB4* is associated with multiple myeloma risk

Writing team: Marco Dicario ^{1#}, Matteo Giaccherini ^{1#}, Alyssa Clay-Gilmour ^{2#}, Angelica Macaudo ³, Juan Sainz ^{4,5,6}, Mitchell J. Machiela ⁷, Malwina Rybicka-Ramos ⁸, Aaron D. Norman ^{9,10}, Agata Tyczyńska ¹¹, Stephen J. Chanock ⁷, Torben Barington ¹², Shaji K. Kumar ¹³, Parveen Bhatti ^{14,15}, Wendy Cozen ¹⁶, Elizabeth E. Brown ¹⁷, Anna Suska ¹⁸, Eva Kannik ¹², Robert Z. Orlowski ¹⁹, Marek Dudziński ²⁰, Ramon Garcia-Sanz ²¹, Marcin Kruszewski ²², Joaquin Martinez-Lopez ²³, Katia Bieder ²⁴, Elżbieta Iskierka-Jazdzewska ²⁵, Matteo Pelosini ²⁶, Sonja I. Berndt ⁷, Małgorzata Rażny ²⁷, Krzysztof Jamroziak ²⁸, S. Vincent Rajkumar ¹³, Artur Jurczyszyn ¹⁸, Annette Juul Vangsted ¹², Pilar Garrido Collado ⁵, Ulla Vogel ²⁹, Jonathan N. Hofmann ⁷, Mario Petrini ³⁰, Aleksandra Butrym ³¹, Susan L. Slager ⁹, Elad Ziv ³², Edyta Subocz ³³, Graham G. Giles ^{34,35,36}, Niels Frost Andersen ¹², Grzegorz Mazur ³⁷, Marzena Watek ^{38,39}, Fabienne Lesueur ⁴⁰, Michelle A. T. Hildebrandt ¹⁹, Daria Zawirska ⁴¹, Lene Hyldahl Ebbesen ¹², Herlander Marques ⁴², Federica Gemignani ¹, Charles Dumontet ⁴³, Judit Várkonyi ⁴⁴, Gabriele Buda ³⁰, Arnon Nagler ²⁴, Agnieszka Druzd-Sitek ⁴⁵, Xifeng Wu ⁴⁶, Katalin Kadar ⁴⁴, Nicola J. Camp ⁴⁷, Norbert Grzasko ⁴⁸, Rosalie Waller ¹⁰, Celine Vachon ^{9*}, Federico Canzian ^{3*}, Daniele Campa ^{1*}

Supplementary table 1. SNPs associated with MM risk in InterLymph ($P < 10^{-4}$)

Supplementary table 2: Minor allelic frequency (MAF) of the ten SNPs analyzed in the replication phase.

Supplementary table 3: effect sizes and P_{values} reported in GWAS catalog for the SNPs selected for replication.

Supplementary figure 1. Flowchart of the process performed to select the SNPs to be replicated in IMMENSE and FinnGen

Supplementary table 1. SNPs associated with MM risk in InterLymph (P<10⁻⁴)

SNP	Locus	Position	Gene	M/m ^b	OR (95%CI)	Pvalue	SNP	Locus	Position	Gene	M/m ^b	OR (OR 95%CI)	Pvalue
rs34517439	1p31.1	chr1:78450517	DNAJB4	C/A	1.30 (1.15-1.48)	4.70x10 ⁻⁵	rs1022206	3q13.13	chr3:110585338	-	T/C	1.18 (1.09-1.28)	8.61x10 ⁻⁵
rs17391694	1p31.1	chr1:78623626	-	C/T	1.31 (1.16-1.48)	1.23x10 ⁻⁵	rs11135441	5q15	chr5:95222277	ELL2	C/T	0.83 (0.76-0.90)	2.34x10 ⁻⁵
rs2279948	1p22.3	chr1:86691285	-	G/A	1.33 (1.15-1.54)	9.94x10 ⁻⁵	rs3777200	5q15	chr5:95234791	ELL2	C/T	0.82 (0.74-0.90)	1.73x10 ⁻⁵
rs6674512	1p22.3	chr1:86714253	-	G/A	1.40 (1.21-1.62)	8.71x10 ⁻⁶	rs56219066 ^a	5q15	chr5:95242931	ELL2	T/C	0.82 (0.75-0.90)	2.22x10 ⁻⁵
rs17129031	1p22.3	chr1:86736892	-	T/C	1.37 (1.18-1.59)	4.18x10 ⁻⁵	rs3777189	5q15	chr5:95253108	ELL2	C/G	0.82 (0.74-0.90)	1.69x10 ⁻⁵
rs7577599 ^a	2p23.3	chr2:25613146	DTNB	T/C	0.79 (0.71-0.88)	2.19x10 ⁻⁵	rs1423269 ^a	5q15	chr5:95255724	ELL2	A/G	0.82 (0.74-0.90)	1.70x10 ⁻⁵
rs3769943	2q24.3	chr2:166186004	SCN2A	G/C	0.84 (0.77-0.92)	6.62x10 ⁻⁵	rs3777184	5q15	chr5:95262044	ELL2	G/C	0.81 (0.74-0.89)	1.64x10 ⁻⁵
rs10187103	2q24.3	chr2:166188694	SCN2A	C/T	0.84 (0.77-0.91)	6.06x10 ⁻⁵	rs4143832	5q31.1	chr5:131862977	AC116366.3	G/T	0.81 (0.73-0.90)	4.66x10 ⁻⁵
rs7420021	2q24.3	chr2:166188699	SCN2A	A/T	0.84 (0.77-0.92)	6.66x10 ⁻⁵	rs537930	5q31.1	chr5:134348703	-	G/T	0.83 (0.76-0.91)	5.09x10 ⁻⁵
rs7581427	2q24.3	chr2:166238034	SCN2A	T/C	0.84 (0.78-0.92)	8.24x10 ⁻⁵	rs1063348	6p21.32	chr6:32627923	HLA-DQB1	G/A	0.84 (0.77-0.92)	7.44x10 ⁻⁵
rs6763508 ^a	3p22.1	chr3:41750989	ULK4	T/C	1.24 (1.11-1.37)	7.17x10 ⁻⁵	rs9372120 ^a	6q21	chr6:106667535	ATG5	T/G	1.23 (1.11-1.35)	4.48x10 ⁻⁵
rs7651190	3p22.1	chr3:41765955	ULK4	A/G	1.25 (1.13-1.39)	2.32x10 ⁻⁵	rs2299864	6q21	chr6:106667994	ATG5	C/T	1.24 (1.12-1.37)	1.96x10 ⁻⁵
rs6599175 ^a	3p22.1	chr3:41786009	ULK4	T/C	1.25 (1.12-1.38)	3.65x10 ⁻⁵	rs3804333	6q21	chr6:106727215	ATG5	C/T	1.24 (1.12-1.37)	2.19x10 ⁻⁵
rs9832037	3p22.1	chr3:41812032	ULK4	T/C	1.24 (1.12-1.37)	6.08x10 ⁻⁵	rs4487645 ^a	7p15.3	chr7:21938240	DNAH11	C/A	0.84 (0.77-0.91)	5.15x10 ⁻⁵
rs73071352 ^a	3p22.1	chr3:41828300	ULK4	A/G	1.26 (1.12-1.40)	6.10x10 ⁻⁵	rs1122979	7q36.1	chr7:150915071	ABCF2	G/A	1.29 (1.14-1.46)	5.35x10 ⁻⁵
rs6768542	3p22.1	chr3:41865474	ULK4	G/A	1.24 (1.12-1.38)	4.45x10 ⁻⁵	rs7812088	7q36.1	chr7:150919829	ABCF2	G/A	1.29 (1.14-1.46)	5.95x10 ⁻⁵
rs114714860	3p22.1	chr3:41882905	ULK4	G/C	1.26 (1.13-1.40)	1.56x10 ⁻⁵	rs13252276	8p23.1	chr8:10047203	-	C/T	0.77 (0.68-0.87)	3.10x10 ⁻⁵
rs6797165	3p22.1	chr3:41887777	ULK4	A/G	1.26 (1.14-1.40)	1.33x10 ⁻⁵	rs1948915 ^a	8q24.21	chr8:128222421	PCAT1	T/C	1.21 (1.11-1.32)	8.04x10 ⁻⁶
rs2683696	3p22.1	chr3:41914898	ULK4	T/C	1.26 (1.14-1.40)	1.30x10 ⁻⁵	rs465530	12q14.3	chr12:65330766	LINC02389	G/T	1.18 (1.09-1.28)	4.94x10 ⁻⁵
rs79211428	3p22.1	chr3:41921810	ULK4	C/T	1.28 (1.15-1.43)	1.18x10 ⁻⁵	rs57968458 ^a	17p11.2	chr17:16820099	-	G/A	1.33 (1.18-1.50)	4.99x10 ⁻⁶
rs1052501 ^a	3p22.1	chr3:41925398	ULK4	T/C	0.79 (0.72-0.88)	1.53x10 ⁻⁵	rs28507905	17p11.2	chr17:16820513	-	C/T	1.33 (1.18-1.50)	1.90x10 ⁻⁶
rs1716983	3p22.1	chr3:41964128	ULK4	A/G	0.80 (0.72-0.89)	2.72x10 ⁻⁵	rs34562254 ^a	17p11.2	chr17:16842991	TNFRSF13B	G/A	1.42 (1.26-1.61)	1.88x10 ⁻⁸
rs7622665	3p22.1	chr3:41970743	ULK4	C/T	0.80 (0.72-0.89)	3.42x10 ⁻⁵	rs4792800	17p11.2	chr17:16845167	TNFRSF13B	A/G	1.37 (1.22-1.55)	3.42x10 ⁻⁷
rs1717027	3p22.1	chr3:41987920	ULK4	C/T	0.80 (0.72-0.89)	2.59x10 ⁻⁵	rs4561508	17p11.2	chr17:16848750	TNFRSF13B	C/T	1.37 (1.21-1.55)	6.45x10 ⁻⁷
rs7372217	3p22.1	chr3:41990122	ULK4	A/G	0.80 (0.72-0.89)	2.79x10 ⁻⁵	rs4273077 ^a	17p11.2	chr17:16849139	TNFRSF13B	A/G	1.32 (1.17-1.49)	1.04x10 ⁻⁵
rs6599192 ^a	3p22.1	chr3:41992408	ULK4	A/G	0.80 (0.72-0.89)	2.51x10 ⁻⁵	rs57166795	17p11.2	chr17:16857177	TNFRSF13B	G/A	1.37 (1.21-1.55)	5.27x10 ⁻⁷
rs2272007 ^a	3p22.1	chr3:41996136	ULK4	C/T	0.80 (0.72-0.89)	2.79x10 ⁻⁵	rs4985726	17p11.2	chr17:16863638	TNFRSF13B	C/G	1.35 (1.20-1.53)	1.57x10 ⁻⁶
rs9856633	3p22.1	chr3:42013850	-	G/A	0.80 (0.72-0.89)	4.31x10 ⁻⁵	rs8132680	21q22.12	chr21:36564709	RUNX1	T/C	1.21 (1.11-1.33)	2.96x10 ⁻⁵

^a SNPs already known to be associated with the risk of developing MM; b: M= the most common allele in controls; m= the less common allele in controls

Supplementary table 2: Minor allelic frequency (MAF) of the ten SNPs analyzed in the replication phase.

SNP	Region	(Alleles) M/m	MAF Interlymph	MAF IMMEnSE	MAF FinnGen
rs34517439	1p31.1	C/A	0.09	0.08	0.13
rs6674512	1p22.3	G/A	0.06	0.06	0.07
rs10187103	2q24.3	C/T	0.31	0.32	0.17
rs1022206	3q13.13	C/T	0.42	0.40	0.37
rs4143832	5q31.1	G/T	0.17	0.21	0.23
rs537930	5q31.1	G/T	0.26	0.26	0.23
rs1063348 ^a	6p21.32	G/A	0.41	0.41	0.49
rs13252276	8p23.1	C/T	0.46	0.43	0.35
rs465530	12q14.3	G/T	0.49	0.48	0.40
rs8132680	21q22.12	T/C	0.25	0.26	0.22

^a: this polymorphism is not present in FinnGen, and therefore the frequency reported was obtained from 1000Genome.

Supplementary table 3: effect sizes and P_{values} reported in GWAS catalog for the SNPs selected for replication.

SNP	Region	(Alleles) M/m _a	Trait	OR (95CI)	P _{value}
rs34517439	1p31.1	C/A	Height	1.03 (1.02-1.04)	1.00E-34
			Body mass index	1.04 (1.02-1.05)	4.00E-24
			Fat-free mass	1.46 (1.28-1.65)	5.00E-28
			Diastolic blood pressure	0.79 (0.72-0.88)	5.00E-21
			Hand grip strength	0.997 (0.995-0.998)	3.00E-12
			Lung cancer	1.14 (1.09-1.18)	2.00E-10
			Psoriasis	1.18 (NA)	4.00E-09
			Smoking initiation (ever regular vs never regular) (MTAG)	1.01 (1.00-1.02)	9.00E-09
			Hair color	NA	2.00E-08
			Lung adenocarcinoma	1.17 (1.10-1.23)	4.00E-08
			Lung cancer in ever smokers	1.15 (1.09-1.21)	7.00E-08
rs6674512	1p22.3	G/A	Male-pattern baldness	0.97 (0.94-0.99)	4.00E-10
rs10187103	2q24.3	C/T	Age of smoking initiation (MTAG)	0.99 (0.98-1.00)	5.00E-09
rs1022206	3q13.13	C/T	Balding type 1	-	2.00E-12
rs4143832	5q31.1	G/T	Eosinophil counts	-	1.00E-10
rs537930	5q31.1	G/T	Height	0.97 (0.94-0.99)	9.00E-09
rs1063348	6p21.32	G/A	Childhood steroid-sensitive nephrotic syndrome	3.33 (2.62-4.23)	9.00E-23
rs13252276	8p23.1	C/T	General factor of neuroticism	1.01 (1.00-1.02)	5.00E-09
rs465530	12q14.3	G/T	Acute graft versus host disease in bone marrow transplantation (recipient effect)	-	4.00E-08
rs8132680	21q22.12	T/C	Heel bone mineral density	0.98 (0.98-0.99)	3.00E-12

Supplementary figure 1. Flowchart of the process performed to select the SNPs to be replicated in IMMEnSE and FinnGen

